Gilead and LEO Pharma partner to develop oral STAT6 programs for inflammatory diseases

From Nasdaq: 2025-01-11 13:34:48

Gilead Sciences, Inc. and LEO Pharma have partnered to develop and commercialize LEO Pharma’s small molecule oral STAT6 programs for inflammatory diseases like atopic dermatitis and asthma. Gilead will acquire LEO Pharma’s preclinical oral STAT6 inhibitors and protein degraders, leading development efforts for oral programs while LEO Pharma focuses on potential topical formulations. The deal gives Gilead global rights for oral programs and LEO Pharma exclusive global rights for topical formulations in dermatology. LEO Pharma could receive up to $1.7 billion, including an upfront payment of $250 million, and both companies will earn royalties on product sales. The partnership is expected to impact Gilead’s 2025 EPS by $0.15 – $0.17.



Read more at Nasdaq: Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program